Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: Towards innovative antirheumatic therapy

被引：76

作者：

Tas, SW ^{[1
]}

Remans, PHJ ^{[1
]}

Reedquist, KA ^{[1
]}

Tak, PP ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL-1100 DD Amsterdam, Netherlands

来源：

CURRENT PHARMACEUTICAL DESIGN | 2005年 / 11卷 / 05期

关键词：

inflammatory disease; rheumatoid arthritis; signal transduction; nuclear factor-kappa B; mitogen-activated protein kinase; reactive oxygen species; novel therapies;

D O I：

10.2174/1381612053381918

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity. and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-kappaB (NF-kappaB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K)/Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.

引用

页码：581 / 611

页数：31

共 426 条

[1] Rheumatoid arthritis and metal compounds - perspectives on the role of oxygen radical detoxification [J].

Aaseth, J ;

Haugen, M ;

Forre, O .

ANALYST, 1998, 123 (01) :3-6

[2] REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO [J].

ABATE, C ;

PATEL, L ;

RAUSCHER, FJ ;

CURRAN, T .

SCIENCE, 1990, 249 (4973) :1157-1161

[3] Proteasome inhibitors as new anticancer drugs [J].

Adams, J .

CURRENT OPINION IN ONCOLOGY, 2002, 14 (06) :628-634

[4]

Åkerlund K, 1999, CLIN EXP IMMUNOL, V115, P32

[5] Roles of STAT3 defined by tissue-specific gene targeting [J].

Akira, S .

ONCOGENE, 2000, 19 (21) :2607-2611

[6] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].

ALESSI, DR ;

CUENDA, A ;

COHEN, P ;

DUDLEY, DT ;

SALTIEL, AR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494

[7] FIBRINOLYTIC AND FIBRIN STABILIZING ACTIVITY OF SYNOVIAL MEMBRANES [J].

ANDERSEN, RB ;

GORMSEN, J .

ANNALS OF THE RHEUMATIC DISEASES, 1970, 29 (03) :287-&

[8] Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis -: Implications for therapy [J].

Andreakos, E ;

Smith, C ;

Kiriakidis, S ;

Monaco, C ;

de Martin, R ;

Brennan, FM ;

Paleolog, E ;

Feldmann, M ;

Foxwell, BM .

ARTHRITIS AND RHEUMATISM, 2003, 48 (07) :1901-1912

[9] A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression [J].

Anest, V ;

Hanson, JL ;

Cogswell, PC ;

Steinbrecher, KA ;

Strahl, BD ;

Baldwin, AS .

NATURE, 2003, 423 (6940) :659-663

[10] THE JUN PROTO-ONCOGENE IS POSITIVELY AUTOREGULATED BY ITS PRODUCT, JUN/AP-1 [J].

ANGEL, P ;

HATTORI, K ;

SMEAL, T ;

KARIN, M .

CELL, 1988, 55 (05) :875-885

← 1 2 3 4 5 6 7 8 9 10 →